Curable metastatic colorectal cancer

Current Oncology Reports

Volumn 13, Issue 3, 2011, Pages 168-176

  Eadens, Matthew J ^a   Grothey, Axel ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chemoembolization; Conversion therapy; Hepatic artery infusion; Hepatic metastases; Liver metastases; Lung metastases; Metastatic colorectal cancer; Neoadjuvant chemotherapy; Radioembolization; Radiofrequency ablation; Stereotactic body radiation therapy; Yttrium 90

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DEXAMETHASONE; DOXORUBICIN; ETHIODIZED OIL; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MICROSPHERE; MITOMYCIN C; OXALIPLATIN; PANITUMUMAB; POLYVINYL ALCOHOL; YTTRIUM 90;

ABDOMINAL PAIN; ARTIFICIAL EMBOLISM; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CHEMOEMBOLIZATION; COLORECTAL CANCER; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG INFUSION; EUROPE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL SYMPTOM; HEPATIC ARTERY; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PROGNOSIS; PROSPECTIVE STUDY; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEREOTACTIC BODY RADIATION THERAPY; UNITED STATES; VOMITING;

ABLATION TECHNIQUES; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; EUROPE; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; NEOADJUVANT THERAPY; NEOPLASM STAGING; SURVIVAL ANALYSIS; UNITED STATES;

EID: 79955880764     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-011-0157-0     Document Type: Review

References (70)

1. Jemal A, Siegel R, Jiaquan X, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. StatBite. At what stage are colorectal cancer patients diagnosed? J Natl Cancer Inst. 2009;101:1114.
3. Labianca R, Beretta GD, Kildani B, et al. Colon cancer. Crit Rev Oncol Hematol. 2010;74:106-33.
4. Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254-9. (Pubitemid 44305540)
5. Ridge JA, Daly JM. Treatment of colorectal hepatic metastases. Surg Gynecol Obstet. 1985;161:597-607. (Pubitemid 16172286)
6. Foster JH. Treatment of metastatic disease of the liver: a skeptic's view. Semin Liver Dis. 1984;4:170-9.
7. Penna C, Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin N Am. 2002;82:1075-90. (Pubitemid 35463085)
8. O'Connell MJ, Campbell ME, Goldberg RM, et al. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol. 2008;26:2336-41.
9. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938-46. (Pubitemid 27106275)
10. Robertson DJ, Stukel TA, Gottlieb DJ, et al. Survival after hepatic resection of colorectal cancer metastases. Cancer. 2009;115:752-9.
11. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759-66. (Pubitemid 34547293)
12. Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer. Cancer. 2007;109:718-26. (Pubitemid 46233233)
13. Tsai MS, Su YH, Ho MC, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol. 2007;14:786-94.
14. Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg. 1995;19:59-71.
15. Charnsangavej C, Clary B, Fong Y, et al.: Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006, 13: 1261-1268. This is an important trial for providing criteria for resectability of liver metastases and the importance of negative margins.
16. DeJong MC, Mayo SC, Pulitano C, et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg. 2009;13:2141-51.
17. Pastorino U, The International Registry of Lung Metastases Writing Committee, et al. Long-term results of lung metastectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113:37-49. (Pubitemid 27034340)
18. Headrick JR, Miller DL, Nagorney DM, et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg. 2001;71:975-80. (Pubitemid 32210413)
19. Adam R, DeHaas RJ, Wicherts DA, et al. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J Clin Oncol. 2008;26:3672-80.
20. Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010;28:493-508.
21. Gravante G, Overton J, Sorge R, et al. Radiofrequency ablation versus resection for liver tumours: an evidence-based approach to retrospective comparative studies. J Gastrointest Surg 2010, In press (Epub ahead of print).
22. Gleisner AL, Choti MA, Assumpcao L, et al. Colorectal Liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg. 2008;143:1204-12.
23. Engstrom PF, Arnoletti JP, Benson 3rd AB, et al. NCCN clinical practice guidelines in oncology: colon cancer. J Natl Compr Canc Netw. 2009;7:778-831.
24. Ruers T, Punt CJ, van Coevorden F, et al.: Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM) [abstract 3526]. Presented at the 2010 ASCO Annual Meeting. Chicago, IL; June 4-8, 2010. The CLOCC trial is the most informative data at the present time for RFA combined with chemotherapy but unfortunately will need longer follow-up to determine the true benefit.
25. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. Ann Surg. 2004;240:644-58. (Pubitemid 39281287)
26. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liveronly metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23:9243-9.
27. Barone C, Nuzzo G, Cassano A, et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer. 2007;97:1035-9. (Pubitemid 47587006)
28. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670-6. (Pubitemid 46797946)
29. Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249:420-5.
30. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-flourouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomized phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;94:798-805.
31. Van Cutsem E, Köhne CH, Zaluski J, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-17.
32. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663-71.
33. Folprecht G, Gruenberger T, Bechstein WO, et al.: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomized phase 2 trial. Lancet Oncol. 2010; 11:38-47. The CELIM trial demonstrated the benefit of adding EGFR inhibitors (cetuximab in this case) to neoadjuvant chemotherapy regimens for metastases.
34. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-9.
35. Okines A, Puerto OD, Cunningham D, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomized phase-III NO16966 trial. Br J Cancer. 2009;101:1033-8.
36. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830-5.
37. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;21:2338-44.
38. Dy GK, Krook JE, Green EM, et al. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol. 2007;25:3469-74. (Pubitemid 47310885)
39. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24:3939-45. (Pubitemid 46630742)
40. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065-72. (Pubitemid 46622116)
41. Brouquet A, Benoist S, Julie C, et al. Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery. 2009;145:362-71.
42. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460-6. (Pubitemid 38444550)
43. Chun YS, Laurent A, Maru D, Vauthey JN. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol. 2009;10:278-86.
44. Wein A, Riedel C, Bruckl W, et al. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology. 2003;64:131-8. (Pubitemid 36173378)
45. Taieb J, Artru P, Paye F, et al. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol. 2005;23:502-9. (Pubitemid 46224226)
46. Nordlinger B, Sorbye H, Glimelius B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet 2008; 371:1007-16. This large international randomized trial demonstrated the benefit of neoadjuvant chemotherapy for hepatic colorectal metastases.
47. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109-16.
48. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24:4976-82. (Pubitemid 46631399)
49. Langer B, Bleiberg H, Labianca R, et al.: Fluorouracil (FU) plus 1-leucovorin (1-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 2002, 21: (abstr 592).
50. Mitry E, Fields ALA, Bleiberg H, et al.: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008; 26:4906-11. This trial demonstrated the benefit of adjuvant chemotherapy for resected metastatic disease by combining results from two prior smaller studies.
51. Ychou, M, Hohenberger W, Thezenas S, et al.: A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol. 2009; 1964-70.
52. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27:3117-25.
53. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluororuracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25:3456-61. (Pubitemid 47310883)
54. Ychou M, Raoul JL, Douillard JY, et al. A phase III randomized trial of LV5FU2 + irinotecan versus LV5FU alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009;20:674-80.
55. Allegra CJ, Yothers G, O'Connell MJ, et al.: Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol 2010, In press (Epub ahead of print).
56. Alberts SR, Sargent DJ, Smyrk TC, et al.: Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup Phase III Trial N0147 (Abstract CRA 3507). J Clin Oncol 2010; 28 (18 Suppl).
57. Power DG, Healey-Bird BR, Kemeny NE. Regional chemotherapy for liver-limited metastatic colorectal cancer. Clin Colorectal Cancer. 2008;7:247-59.
58. Mocellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer (review). Cochrane Database Syst Rev. 2009;8:CD007823.
59. Nelson RL, Freels S. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer meta-static to the liver (review). Cochrane Database Syst Rev. 2006;18: CD003770.
60. Alberts SR, Roh MS, Mahoney MR, et al. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66. J Clin Oncol. 2010;28:853-8.
61. Kemeny NE, Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27:3465-71.
62. Martin RCG, Robbins K, Tomalty D, et al. Transarterial chemo-embolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol. 2009;7:80.
63. Albert M, Kiefer MV, Sun W, et al.: Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 2010, In press (Epub ahead of print).
64. Vogl TJ, Gruber T, Balzer JO, et al. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology. 2009;250:281-9.
65. Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radio-embolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer. 2009;115:1849-58.
66. Cianni R, Urigo C, Notarianni E, et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol. 2009;32:1179-86.
67. Hong K, McBride JD, Georgiades CS, et al. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium- 90 radioembolization. J Vasc Interv Radiol. 2009;20:360-7.
68. Townsend A, Price T, Karapetis C. Selective internal radiation therapy for liver metastases from colorectal cancer. Cochrane Database Syst Rev. 2009;7:CD007045.
69. Hoyer M, Roed H. Traberg Hansen A, et al.: Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45:823-30. (Pubitemid 44423128)
70. Katz AW, Carey-Sampson M, Muhs AG, et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiation Oncology Biol Phys. 2007;67:793-8. (Pubitemid 46215888)